COVID-19 and celiac disease: A pathogenetic hypothesis for a celiac outbreak - PubMed

Affiliations

Affiliations

• 1 Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza University of Rome, Rome, Italy.
• 2 Hepatology Gastroenterology and Nutrition Unit, "Bambino Gesù" Children Hospital, Rome, Italy.

• PMID: 34145702
• PMCID: PMC8420168
• DOI: 10.1111/ijcp.14452

Item in Clipboard

Chiara Maria Trovato  et al. Int J Clin Pract . 2021 Sep .

Free PMC article

Affiliations

• 1 Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza University of Rome, Rome, Italy.
• 2 Hepatology Gastroenterology and Nutrition Unit, "Bambino Gesù" Children Hospital, Rome, Italy.

• PMID: 34145702
• PMCID: PMC8420168
• DOI: 10.1111/ijcp.14452

Item in Clipboard

Abstract

Background: A growing body of evidence supports the intestinal trophism of SARS-CoV-2, with ciliated cells and intestinal enterocytes being target cells because of the high expression of ACE2 and TMPRSS2. Indeed, COVID-19 promotes a "cytokine storm" in the intestinal mucosa: the resulting epithelial damage leads to increased barrier permeability, allowing the passage of gliadin in the intestinal lamina.

Methods: Based on current literature, we hypothesize the role of COVID-19 as a potential trigger factor for celiac disease in predisposed patients.

Conclusions: Genetically predisposed patients could be more likely to develop celiac disease following SARS-CoV-2 infection, making COVID-19 a candidate culprit for a potential outbreak of celiac disease in the forthcoming future.

© 2021 John Wiley & Sons Ltd.

Conflict of interest statement

The authors declare no conflicts of interest for the present study.

Similar articles

• Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3.

  Lammers KM, Lu R, Brownley J, Lu B, Gerard C, Thomas K, Rallabhandi P, Shea-Donohue T, Tamiz A, Alkan S, Netzel-Arnett S, Antalis T, Vogel SN, Fasano A. Lammers KM, et al. Gastroenterology. 2008 Jul;135(1):194-204.e3. doi: 10.1053/j.gastro.2008.03.023. Epub 2008 Mar 21. Gastroenterology. 2008. PMID: 18485912 Free PMC article.

• Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity.

  Hollon J, Puppa EL, Greenwald B, Goldberg E, Guerrerio A, Fasano A. Hollon J, et al. Nutrients. 2015 Feb 27;7(3):1565-76. doi: 10.3390/nu7031565. Nutrients. 2015. PMID: 25734566 Free PMC article. Clinical Trial.

• Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients.

  Kumar A, Faiq MA, Pareek V, Raza K, Narayan RK, Prasoon P, Kumar P, Kulandhasamy M, Kumari C, Kant K, Singh HN, Qadri R, Pandey SN, Kumar S. Kumar A, et al. Med Hypotheses. 2020 Nov;144:110271. doi: 10.1016/j.mehy.2020.110271. Epub 2020 Sep 13. Med Hypotheses. 2020. PMID: 33254575 Free PMC article.

• Age and gender differences in ACE2 and TMPRSS2 expressions in oral epithelial cells.

  Peng J, Sun J, Zhao J, Deng X, Guo F, Chen L. Peng J, et al. J Transl Med. 2021 Aug 19;19(1):358. doi: 10.1186/s12967-021-03037-4. J Transl Med. 2021. PMID: 34412632 Free PMC article.

• Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.

  Mahmoud IS, Jarrar YB. Mahmoud IS, et al. Mol Biol Rep. 2021 May;48(5):4667-4675. doi: 10.1007/s11033-021-06390-1. Epub 2021 May 22. Mol Biol Rep. 2021. PMID: 34023987 Free PMC article. Review.

Cited by

• Celiac Disease and Targeting the Molecular Mechanisms of Autoimmunity in COVID Pandemic.

  Ailioaie LM, Ailioaie C, Litscher G, Chiran DA. Ailioaie LM, et al. Int J Mol Sci. 2022 Jul 13;23(14):7719. doi: 10.3390/ijms23147719. Int J Mol Sci. 2022. PMID: 35887067 Free PMC article. Review.

• New-onset celiac disease in children during COVID-19 pandemic.

  Cakir M, Guven B, Issi F, Ozkaya E. Cakir M, et al. Acta Paediatr. 2022 Feb;111(2):383-388. doi: 10.1111/apa.16173. Epub 2021 Nov 11. Acta Paediatr. 2022. PMID: 34738264 Free PMC article.

References

1. 1. Hussman JP. Cellular and molecular pathways of COVID‐19 and potential points of therapeutic intervention. Front Pharmacol. 2020;11:1169. - PMC - PubMed
2. 1. Camargo SMR, Vuille‐Dit‐Bille RN, Meier CF, Verrey F. ACE2 and gut amino acid transport. Clin Sci (Lond). 2020;134:2823‐2833. - PubMed
3. 1. Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS‐CoV‐2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5:eabc3582. - PMC - PubMed
4. 1. Uzzan M, Corcos O, Martin JC, Treton X, Bouhnik Y. Why is SARS‐CoV‐2 infection more severe in obese men? The gut lymphatics ‐ lung axis hypothesis. Med Hypotheses. 2020;144:110023. - PMC - PubMed
5. 1. Wu D, Yang XO. TH17 responses in cytokine storm of COVID‐19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368‐370. - PMC - PubMed